Smoking Cessation: Pharmacotherapy and 5 A's

Nicotine addiction involves complex neurobiological mechanisms that make tobacco cessation one of the most challenging behavior changes in medicine. Nicotine (the primary addictive compound in tobacco, not the primary carcinogen) crosses the blood-brain barrier within 10-20 seconds of inhalation and binds to nicotinic acetylcholine receptors (nAChRs), particularly the alpha4beta2 subtype, in the ventral tegmental area (VTA) of the midbrain. Receptor activation stimulates dopamine release in the nucleus accumbens (the brain's reward center), producing pleasure, improved concentration, reduced anxiety, and appetite suppression. With chronic exposure, nAChR desensitization and upregulation occur: the brain increases receptor density to compensate for desensitization, creating a state where higher nicotine levels are needed to achieve the same effect (tolerance). When nicotine levels fall (overnight, between cigarettes), unoccupied upregulated receptors produce withdrawal symptoms: irritability, anxiety, difficulty concentrating, increased appetite, depressed mood, and intense craving. This cycle of reward-tolerance-withdrawal-relief drives compulsive use. Nicotine also activates the hypothalamic-pituitary-adrenal axis (cortisol release), noradrenergic system (locus coeruleus), and serotonergic system, contributing to mood regulation effects. Conditioned associations (environmental cues paired with smoking) create powerful triggers through Pavlovian conditioning in the hippocampus...